Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. A snapshot of POPC.
  • Fig. S2. Time series of secondary structures of two copies of apoC-II in 1-μs-long simulation.
  • Fig. S3. Last configuration of two copies of apoC-II in 1-μs-long simulation.
  • Fig. S4. Time series of secondary structures of two copies of D6PV.
  • Fig. S5. Plasma TG in apoC-II–deficient mice treated with D6PV.
  • Fig. S6. ApoC-III displacement from HDL by D6PV.
  • Fig. S7. Effect of D6PV on binding of apoC-III to lipoproteins.
  • Fig. S8. Lipoprotein lipid distribution in hAPOC3-Tg × Ldlr−/− mice treated with D6PV.
  • Fig. S9. Plasma TG in iLpl−/− and noninduced Lplfl/fl mice treated with D6PV.
  • Fig. S10. Plasma NEFA in D6PV-treated mice.
  • Fig. S11. PK results of mice and nonhuman primates given a single intravenous dose of D6PV.
  • Fig. S12. D6PV binding affinity to lipoproteins.
  • Fig. S13. Effect of D6PV on cholesterol efflux and pre-beta HDL formation.
  • Fig. S14. Area per POPC in the lipid trilayer simulation.
  • Table S1. Liver function tests in apoC-II–deficient mice after D6PV treatment.
  • Table S2. List of all-atom MD simulations.
  • References (4756)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: